122 related articles for article (PubMed ID: 26345832)
1. Associations between the SRD5A2 gene V89L and TA repeat polymorphisms and breast cancer risk: a meta-analysis.
Zhang D; Li Q; Qu HC; Yu T; Liu YR
Genet Mol Res; 2015 Aug; 14(3):9004-12. PubMed ID: 26345832
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
[TBL] [Abstract][Full Text] [Related]
3. SRD5A2 gene polymorphisms affect the risk of breast cancer.
Francis A; Sarkar S; Pooja S; Surekha D; Rao DR; Rao L; Ramachandra L; Vishnupriya S; Satyamoorthy K; Thangaraj K; Rajender S
Breast; 2014 Apr; 23(2):137-41. PubMed ID: 24365257
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
5. A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.
Yang C; Hamajima N; Iwata H; Saito T; Matsuo K; Hirose K; Inoue M; Takezaki T; Tajima K
Breast Cancer Res; 2002; 4(4):R8. PubMed ID: 12100746
[TBL] [Abstract][Full Text] [Related]
6. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
8. TA repeat polymorphism of the 5alpha-reductase gene and breast cancer.
Bharaj B; Scorilas A; Giai M; Diamandis EP
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):387-93. PubMed ID: 10794483
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of 17 β-hydroxysteroid dehydrogenase 3 and the risk of hypospadias.
Sata F; Kurahashi N; Ban S; Moriya K; Tanaka KD; Ishizuka M; Nakao H; Yahata Y; Imai H; Kakizaki H; Nonomura K; Kishi R
J Sex Med; 2010 Aug; 7(8):2729-38. PubMed ID: 20059664
[TBL] [Abstract][Full Text] [Related]
10. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):618-24. PubMed ID: 12869400
[TBL] [Abstract][Full Text] [Related]
11. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Spurdle AB; Hopper JL; Chen X; Dite GS; McCredie MR; Giles GG; Venter DJ; Southey MC; Purdie DM; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1287-93. PubMed ID: 11751447
[TBL] [Abstract][Full Text] [Related]
12. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
13. Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Scorilas A; Bharaj B; Giai M; Diamandis EP
Br J Cancer; 2001 Mar; 84(6):760-7. PubMed ID: 11259089
[TBL] [Abstract][Full Text] [Related]
14. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
[TBL] [Abstract][Full Text] [Related]
15. Steroid 5-alpha-reductase type 2 (SRD5A2) gene V89L polymorphism and hypospadias risk: A meta-analysis.
Zhang K; Li Y; Mao Y; Ma M
J Pediatr Urol; 2017 Dec; 13(6):630.e1-630.e9. PubMed ID: 28713005
[TBL] [Abstract][Full Text] [Related]
16. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
[TBL] [Abstract][Full Text] [Related]
17. Longer TA repeat but not V89L polymorphisms in the SRD5A2 gene may confer acne risk in the Chinese population.
Hu X; Ding W; Jin X; Wang J; Zou D; Chen Y
Postepy Dermatol Alergol; 2018 Feb; 35(1):33-38. PubMed ID: 29610568
[TBL] [Abstract][Full Text] [Related]
18. The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
van Gils CH; Onland-Moret NC; Roest M; van Noord PA; Peeters PH
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1194-9. PubMed ID: 14652280
[TBL] [Abstract][Full Text] [Related]
19. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
Li J; Coates RJ; Gwinn M; Khoury MJ
Am J Epidemiol; 2010 Jan; 171(1):1-13. PubMed ID: 19914946
[TBL] [Abstract][Full Text] [Related]
20. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
